Brief: Nanobiotix H1 Net Loss Attributable To Common Shareholders Widens To EUR 30.4 Mln

Nanobiotix SA

09/09/2021 07:08

Sept 9 (Reuters) - NANOBIOTIX SA  NANOB.PA :
    * PUBLISHED ON WEDNESDAY POSITIVE DATA FROM STUDY 102
EXPANSION
INCLUDED OVERALL OBJECTIVE RESPONSE RATE OF 82.5% AND A COMPLETE
RESPONSE RATE OF 62.5% IN HIGHLY VULNERABLE, ELDERLY PATIENT
POPULATION
    * CONTINUED SUPPORT FOR PLANNED INITIATION OF PIVOTAL PHASE
III
GLOBAL REGISTRATION STUDY IN LOCALLY ADVANCED HEAD AND NECK
SQUAMOUS CELL CARCINOMA IN LATE Q4
    * POSITIVE DATA FROM ONGOING STUDY 1100 SHOWED THAT NBTXR3
IN
COMBINATION WITH ANTI-PD-1 RESULTED IN TUMOR REGRESSION IN 76.9%
OF EVALUABLE PATIENTS REGARDLESS OF PRIOR ANTI-PD-1 EXPOSURE
    * INTENDS TO INITIATE DISCUSSIONS WITH REGULATORY
AUTHORITIES IN
H2 REGARDING POTENTIAL REGISTRATION PATHWAY FOR THIS
IMMUNOTHERAPY COMBINATION
    * END-JUNE CASH AND CASH EQUIVALENTS EUR 102.3 MILLION 
    * NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS FOR SIX
MONTHS
ENDED JUNE 30 WAS EUR 30.4 MILLION, OR EUR 0.88 PER SHARE VS
LOSS OF EUR 20.6 MILLION, OR EUR 0.91 PER SHARE YEAR AGO

        
 Source text for Eikon:  ID:nBw3BLT4fa 
    
 Further company coverage:  NANOB.PA  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))